SG11201910096RA - Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use - Google Patents
Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and useInfo
- Publication number
- SG11201910096RA SG11201910096RA SG11201910096RA SG11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- boost
- adimab
- lebanon
- lucent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 5
- 241000699670 Mus sp. Species 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 3
- 238000002649 immunization Methods 0.000 abstract 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101150015280 Cel gene Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 208000000260 Warts Diseases 0.000 abstract 1
- 230000022534 cell killing Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 201000010153 skin papilloma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503315P | 2017-05-08 | 2017-05-08 | |
| PCT/US2018/031705 WO2018208864A1 (en) | 2017-05-08 | 2018-05-08 | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910096RA true SG11201910096RA (en) | 2019-11-28 |
Family
ID=64104990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912494TA SG10201912494TA (en) | 2017-05-08 | 2018-05-08 | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use |
| SG11201910096R SG11201910096RA (en) | 2017-05-08 | 2018-05-08 | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912494TA SG10201912494TA (en) | 2017-05-08 | 2018-05-08 | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11542330B2 (ja) |
| EP (1) | EP3621641A4 (ja) |
| JP (3) | JP7393207B2 (ja) |
| KR (1) | KR20200053437A (ja) |
| CN (3) | CN110913895B (ja) |
| AU (1) | AU2018266711A1 (ja) |
| BR (1) | BR112019023111A2 (ja) |
| CA (1) | CA3062825A1 (ja) |
| MX (2) | MX2019013184A (ja) |
| SG (2) | SG10201912494TA (ja) |
| WO (1) | WO2018208864A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022536247A (ja) * | 2019-06-07 | 2022-08-15 | アディマブ・リミテッド・ライアビリティ・カンパニー | 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法 |
| KR20220035368A (ko) * | 2019-06-07 | 2022-03-22 | 아디맵 엘엘씨 | 조작된 ph-의존성 항-cd3 항체, 및 이의 생성 및 사용 방법 |
| US20230203119A1 (en) | 2019-08-15 | 2023-06-29 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| WO2021055669A1 (en) * | 2019-09-20 | 2021-03-25 | Adimab, Llc | Fc variants with reduced effector function |
| CA3164818A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| CN115052897B (zh) * | 2020-01-28 | 2024-06-21 | 湖南远泰生物技术有限公司 | PLAP-CD3ε双特异性抗体 |
| JP2023523336A (ja) | 2020-04-27 | 2023-06-02 | ツイスト バイオサイエンス コーポレーション | コロナウイルス用の変異体核酸ライブラリー |
| CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
| AU2021358033A1 (en) * | 2020-10-07 | 2023-05-04 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
| CN114539415B (zh) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 |
| CN112578117B (zh) * | 2021-02-22 | 2021-05-25 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用 |
| CN112698044B (zh) * | 2021-03-23 | 2021-06-22 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 靶向治疗后免疫状态评价装置及方法 |
| KR20240082402A (ko) * | 2021-10-07 | 2024-06-10 | 내셔날 리서치 카운실 오브 캐나다 | 항-cd3 단일클론 항체 및 치료용 작제물 |
| CN118076387A (zh) * | 2021-10-08 | 2024-05-24 | 艾贝乐医药科技有限公司 | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 |
| CN114573705B (zh) * | 2022-03-17 | 2024-05-14 | 杭州师范大学 | 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| CN116925232A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 靶向ceacam和cd3的多特异性抗体及其用途 |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629011B1 (en) * | 2003-05-31 | 2010-01-13 | Micromet AG | Human anti-human cd3 binding molecules |
| SG155883A1 (en) | 2004-06-03 | 2009-10-29 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| JP6012473B2 (ja) * | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| JP6205363B2 (ja) * | 2011-09-26 | 2017-09-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | ハイブリッド定常領域 |
| SG10201702396QA (en) * | 2012-03-28 | 2017-04-27 | Sanofi Sa | Antibodies to bradykinin b1 receptor ligands |
| DK3736292T3 (da) | 2013-12-17 | 2024-07-22 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
| EP3091032A1 (en) | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
-
2018
- 2018-05-08 SG SG10201912494TA patent/SG10201912494TA/en unknown
- 2018-05-08 KR KR1020197036219A patent/KR20200053437A/ko not_active Application Discontinuation
- 2018-05-08 JP JP2019561267A patent/JP7393207B2/ja active Active
- 2018-05-08 AU AU2018266711A patent/AU2018266711A1/en active Pending
- 2018-05-08 US US16/611,832 patent/US11542330B2/en active Active
- 2018-05-08 CN CN201880045633.0A patent/CN110913895B/zh active Active
- 2018-05-08 EP EP18798898.5A patent/EP3621641A4/en active Pending
- 2018-05-08 CN CN202410287775.5A patent/CN118184781A/zh active Pending
- 2018-05-08 MX MX2019013184A patent/MX2019013184A/es unknown
- 2018-05-08 CN CN202410287712.XA patent/CN118562001A/zh active Pending
- 2018-05-08 BR BR112019023111-0A patent/BR112019023111A2/pt unknown
- 2018-05-08 SG SG11201910096R patent/SG11201910096RA/en unknown
- 2018-05-08 WO PCT/US2018/031705 patent/WO2018208864A1/en unknown
- 2018-05-08 CA CA3062825A patent/CA3062825A1/en active Pending
-
2019
- 2019-11-05 MX MX2024005009A patent/MX2024005009A/es unknown
-
2022
- 2022-11-11 US US18/054,588 patent/US20230151097A1/en active Pending
- 2022-12-01 JP JP2022193173A patent/JP2023014324A/ja active Pending
-
2024
- 2024-02-01 JP JP2024014044A patent/JP2024032937A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024032937A (ja) | 2024-03-12 |
| EP3621641A1 (en) | 2020-03-18 |
| JP2023014324A (ja) | 2023-01-26 |
| RU2019139334A3 (ja) | 2021-08-25 |
| CN118562001A (zh) | 2024-08-30 |
| SG10201912494TA (en) | 2020-02-27 |
| AU2018266711A1 (en) | 2019-11-28 |
| US20230151097A1 (en) | 2023-05-18 |
| KR20200053437A (ko) | 2020-05-18 |
| CA3062825A1 (en) | 2018-11-15 |
| WO2018208864A1 (en) | 2018-11-15 |
| US20200190189A1 (en) | 2020-06-18 |
| MX2019013184A (es) | 2020-02-07 |
| CN118184781A (zh) | 2024-06-14 |
| US11542330B2 (en) | 2023-01-03 |
| CN110913895B (zh) | 2024-04-02 |
| MX2024005009A (es) | 2024-05-10 |
| CN110913895A (zh) | 2020-03-24 |
| EP3621641A4 (en) | 2021-03-03 |
| RU2019139334A (ru) | 2021-06-09 |
| BR112019023111A2 (pt) | 2020-07-28 |
| JP7393207B2 (ja) | 2023-12-06 |
| JP2020518650A (ja) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201811405QA (en) | Improved differentiation method | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201804710TA (en) | Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
| SG11201903340TA (en) | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs |